Last updated: July 25, 2026
Alvimopan (Entereg; The Medicines Company) is an oral peripheral μ-opioid receptor antagonist for postoperative ileus (POI). The product has had limited long-term market share in a shrinking, guideline-influenced POI segment, facing sustained generic and competitive pressure. The financial trajectory has been characterized by early uptake, subsequent maturity, and then revenue erosion tied to payer tightening, utilization shifts, and—depending on jurisdiction and dispensing channels—potential erosion from competitive entries and formulary outcomes.
What is alvimopan (Entereg) and where does it sell in the POI market?
Alvimopan is dosed orally around the time of surgery and continued postoperatively under a dosing schedule intended to reduce the duration of postoperative ileus. Its addressable market is hospitals with high volumes of bowel resections and colorectal surgery. The commercial logic is procedural and hospital-driven rather than office-based: adoption is driven by (1) clinical pathway standardization, (2) formulary access, and (3) pharmacy and nursing workflow fit.
POI demand drivers and constraints
- Surgical volume mix: colorectal and bowel procedures drive “use per case.”
- Clinical pathways: ERAS protocols and enhanced recovery pathways influence POI prophylaxis choices.
- Hospital contracting: access is negotiated via pharmacy benefit management (PBM) and group purchasing organization (GPO) frameworks.
Where the product typically wins
- High-volume inpatient surgery centers with strong POI pathway adoption.
- Settings where the clinical team can operationalize perioperative dosing and post-op monitoring.
What market dynamics have shaped alvimopan’s revenue performance?
Core forces affecting financial trajectory
- Narrow indication and procedure specificity
- Uptake that is pathway-dependent and therefore slower to expand than broader analgesics or antiemetics
- High payer scrutiny on cost-effectiveness for POI duration reduction
- Competition from alternative perioperative ileus strategies (multimodal ERAS regimens and other supportive interventions)
Payer and formulary pressures
POI interventions are evaluated against hard endpoints like time-to-return-of-bowel-function and length of stay. Hospitals often prefer tools with lower acquisition cost, simpler administration, or alignment with existing ERAS bundles. That structure tends to compress long-term price and limits “sustained share expansion.”
Provider economics
The decision to stock and dispense is tied to predictable case volumes. If a hospital uses fewer bowel resections or adopts a standardized ERAS POI approach that reduces incremental benefit, alvimopan utilization falls even if clinical outcomes are acceptable.
Supply chain and execution
Because POI is time-sensitive, in-hospital logistics matter: stocking, perioperative order sets, and administration compliance drive realized demand versus theoretical demand.
When does alvimopan lose exclusivity and what does that mean for sales?
Key commercial implication: exclusivity and patent risk determine whether a full generic replacement is feasible in a given geography and timeframe. For a hospital-administered prescription product like alvimopan, even the presence of competing products does not automatically translate into rapid volume loss; contracting and tender outcomes often delay switching.
A complete exclusivity map requires jurisdiction-specific patent and regulatory event data tied to the branded label and any additional formulation/manufacturing innovations. Without a complete set of Orange Book listings and patent-term-calculation inputs tied to each marketed strength and dosage form, a defensible loss-of-exclusivity date cannot be produced here.
What generic entry risks exist for alvimopan?
Primary risk channel: FDA-led generic competition or authorized generics in the US if patent and exclusivity hurdles clear. Secondary risk channels include:
- Competitive substitution within formularies if multiple therapeutic options reduce POI duration.
- Contracting strategies that drive down net price through tenders, preferred drug lists, or switch-to-generic programs once a legally marketable alternative is available.
For hospital products, market share shifts depend on:
- Pharmacy director and therapeutics committee decisions
- Switch policies in group purchasing contracts
- Prior authorization and inventory management rules
A full Paragraph IV and litigation risk assessment requires Orange Book patent lists (US) and associated FDA challenge and court-docket data, which are not included in the available inputs for this response.
What is the Orange Book status of alvimopan?
Orange Book status: not provided in the available input set, so it cannot be stated accurately here. Orange Book listings are the basis for determining the controlling patents, expiration dates, exclusivity periods, and whether there are any “listed” drug product application numbers tied to specific dosage forms and strengths.
How strong is the patent estate for alvimopan and what formulations are protected?
A patent strength assessment for alvimopan requires:
- Listed US patents by drug product (Orange Book)
- Patent families for drug substance, drug product formulation, and method-of-use
- Expiration dates and remaining unexpired terms by jurisdiction
- Any terminal disclaimers, PTA adjustments, and exclusivity overlays
Those data are not available in the current inputs, so this response cannot produce a complete estate strength table by mechanism (composition vs method-of-use vs formulation) or by claim coverage.
Which companies are competing with alvimopan and how does it compare commercially?
The competitive set in POI is typically “within surgery pathway choices,” meaning comparison is not only direct product-to-product. The decision set often includes:
- Multimodal ERAS regimens and opioid-sparing strategies
- Supportive interventions targeting nausea, pain, and mobility
- Alternative pharmacologic or non-pharmacologic approaches depending on institutional protocols
A direct commercial comparison between branded alvimopan and specific competing brands/generics requires market-share data by competitor and time, which is not included in the available inputs for this response.
What patent litigation affects alvimopan and how does it influence market timing?
Patent litigation influences market timing through:
- Court injunctions or settlement-driven “launch carve-outs”
- Carve-out periods tied to specific strengths, dosage forms, or indications
- Authorized generic timelines or market-share allocation after settlements
A litigation timeline for alvimopan requires case captions, court venues, docket events, and settlement dates, which are not available in the current inputs.
How do settlements and licensing deals change the financial trajectory?
For hospital-administered products, settlements and licenses can:
- Delay generic entry by years (in exchange for exclusivity or royalties)
- Define at-risk launch windows by strength/dosage form
- Include supply agreements affecting net revenue and gross margin
A credible financial-impact analysis requires documented settlement terms and effective dates. No deal-specific data is available in the current inputs.
What FDA regulatory status does alvimopan have and what does it imply for future launches?
Regulatory status (approval history, labeling stability, supplement changes, REMS-like constraints if any, and any post-marketing risk-management requirements) affects:
- Commercial forecast via label restrictions
- Formulation lifecycle via manufacturing changes
- Eligibility pathways for biosimilar/generic-like competition (where applicable)
A precise FDA status summary for alvimopan cannot be produced without the actual FDA review and labeling record inputs.
What are the revenue drivers and cost structure that determine margin?
For a hospital-lane oral product, key revenue drivers include:
- Volume per surgical case and persistence over time
- Net price after rebates and contracting mechanisms
- Specialty distributor and wholesaler channel dynamics
- Formulary mix and patient-shift patterns across institutions
Key margin pressure vectors include:
- Contract-driven price reductions
- Increased distribution costs and smaller batch runs if demand declines
- Loss of volume due to pathway substitution
- Competitive promotional spend and tendering costs
A quantified financial trajectory (annual revenue, gross margin, and unit trends by year) is not provided in the current inputs, so this response cannot anchor outcomes to numeric historical financial statements.
Is alvimopan trending toward a decline or stabilization in 2024–2026?
Given the product’s narrow indication, hospitalization-driven procurement, and typical maturation dynamics for specialty perioperative drugs, the baseline market pattern is: early adoption, then plateau, then gradual erosion when payer contracting tightens and alternative approaches gain share. Whether stabilization occurs depends on:
- Residual unmet demand in high-volume centers
- Continued guideline alignment and pathway integration
- The timing and legality of any competitive entry
A data-driven 2024–2026 forecast requires market data and regulatory/patent clearance context that are not included in the available inputs.
Key Takeaways
- Alvimopan targets POI and is commercially dependent on hospital surgical pathways rather than broad outpatient prescribing.
- The long-run financial trajectory is shaped by narrow indication size, payer formulary contracting, and substitution within ERAS and multimodal perioperative strategies.
- A defensible exclusivity, Orange Book, patent-strength, and generic-entry timeline cannot be stated here because the underlying patent and FDA regulatory listing data are not available in the provided inputs.
- Competitive risk is real but switching timing in hospital formularies is contract-driven and can lag behind legal entry.
FAQs
1) What hospital departments control alvimopan adoption and switching?
Typically Pharmacy and Therapeutics committees, surgical ERAS pathway leadership, and inpatient pharmacy directors.
2) How does ERAS implementation affect alvimopan utilization?
ERAS adoption can reduce incremental POI prevention benefit if opioid-sparing and supportive measures already lower ileus metrics, lowering marginal demand.
3) What dosing compliance factors influence realized revenue?
Order set integration, perioperative timing adherence, and post-op administration compliance drive demand realization.
4) What net-price levers matter most for hospital products like alvimopan?
Rebates, GPO pricing, tender outcomes, and formulary tier placement are the dominant net-price drivers.
5) What are the main legal entry barriers for generics of hospital drugs?
Patent listings, exclusivity periods, and any FDA-led litigation or settlement terms that define at-risk launch timing.
References
No sources were provided in the available input set.
